Denali Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord Injury, multiple sclerosis, Niemann-Pick disease, stroke, Alzheimer’s disease, amyotrophic lateral sclerosis and diabetic neuropathy, among others.
Senya Pharmaceuticals Inc. has described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurological disorders.
Denali Therapeutics Inc. has patented new NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord Injury, leukoencephalopathy, mitochondrial disease, multiple sclerosis, Niemann-Pick disease, spinal muscular atrophy and stroke, among others.
Sironax has described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis, traumatic brain injury, diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
Artivila Therapeutics (Shenzhen) Co. Ltd. has identified NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of Alzheimer's and Parkinson's diseases, multiple sclerosis, amyotrophic lateral sclerosis and peripheral neuropathy.
